← Back to Search

Glucagon-like peptide-1 receptor agonist

Tirzepatide for Obesity

Phase 3
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have overweight, as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart, with at least 1 weight-related comorbidity (dyslipidemia, pre-hypertension, hypertension, nonalcoholic fatty liver disease, obstructive sleep apnea, prediabetes, documented preexisting condition of Type 2 Diabetes)
Participants with Type 2 Diabetes Mellitus (T2DM) who have been treated with either diet and exercise alone or stable treatment with metformin for at least 90 days prior to screening and have a HbA1c<9.0%
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 72
Awards & highlights

Study Summary

This trial will evaluate the safety and effectiveness of a drug for adolescents with obesity and related conditions. It will last 90 weeks with up to 25 visits.

Who is the study for?
This trial is for adolescents with obesity (BMI ≥95th percentile) or overweight with weight-related issues like high cholesterol, high blood pressure, liver disease, sleep apnea, or prediabetes. Those treated for Type 2 Diabetes with diet/exercise or metformin can join if their HbA1c is below 9.0%.Check my eligibility
What is being tested?
The study tests the safety and effectiveness of Tirzepatide, a medication given once weekly to help manage obesity in teens. It's compared against a placebo over about 90 weeks and includes up to 25 visits to check progress.See study design
What are the potential side effects?
Possible side effects of Tirzepatide may include digestive problems like nausea or diarrhea, potential low blood sugar levels especially in those also taking diabetes medications, and possibly thyroid tumors.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am overweight according to BMI charts for my age and sex, and I have a weight-related health issue.
Select...
I have Type 2 Diabetes, treated with diet, exercise, or metformin, and my HbA1c is below 9.0%.
Select...
My BMI is in the top 5% for my age and sex.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 72
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 72 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent Change from Baseline in Body Mass Index (BMI)
Secondary outcome measures
Change from Baseline in Body Weight
Change from Baseline in Body Weight Percentile based on Sex and Age-specific Growth Charts
Change from Baseline in Diastolic Blood Pressure
+8 more

Side effects data

From 2022 Phase 3 trial • 210 Patients • NCT05024032
40%
Diarrhoea
30%
Nausea
27%
Decreased appetite
23%
Upper respiratory tract infection
19%
Abdominal distension
11%
Gastroenteritis
11%
Vomiting
9%
Abortion induced
9%
Flatulence
7%
Abdominal pain upper
7%
Gingivitis
7%
Amylase increased
7%
Lipase increased
6%
Injection site reaction
6%
Menstruation irregular
6%
Abdominal pain
4%
Hepatic function abnormal
4%
Hyperuricaemia
3%
Uterine polyp
3%
Dizziness
3%
Vaginal infection
1%
Supraventricular tachycardia
1%
Hand fracture
1%
Hiccups
100%
80%
60%
40%
20%
0%
Study treatment Arm
10 mg Tirzepatide
15 mg Tirzepatide
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TirzepatideExperimental Treatment1 Intervention
Participants will receive tirzepatide subcutaneously (SC).
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tirzepatide
2019
Completed Phase 3
~5560

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for obesity, such as Tirzepatide, work by targeting hormonal pathways that regulate appetite and glucose metabolism. Tirzepatide is a dual agonist for GIP and GLP-1 receptors, which enhances insulin secretion, reduces glucagon levels, and slows gastric emptying, leading to reduced appetite and increased satiety. Other GLP-1 receptor agonists function similarly by mimicking the incretin hormones, which help to control blood sugar levels and reduce food intake. These mechanisms are important for obesity patients as they address both weight loss and metabolic health, providing a comprehensive approach to treatment.

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,627 Previous Clinical Trials
3,217,643 Total Patients Enrolled
57 Trials studying Obesity
51,675 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,351 Previous Clinical Trials
416,316 Total Patients Enrolled
40 Trials studying Obesity
31,394 Patients Enrolled for Obesity
~100 spots leftby Oct 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top